Specifically, we aim to (1) evaluate the prevalence and significance of elevated anti-TPO and hsCRP levels in SCH compared to other thyroid disorder subgroups and healthy controls; (2) examine the relationship between anti-TPO and hsCRP levels and their potential interactions in driving systemic inflammation; and (3) assess the association between elevated levels of these markers and the risk of progression to overt hypothyroidism, CVD, or metabolic complications. The gene discussed is TPO; the disease is spindle cell hemangioma.